Markets:

Overview

News

Currencies

International

Treasuries

Theravance Biopharma, Inc. - Ordinary Shares (NQ:TBPH)

20.01 -0.10 (-0.50%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Theravance Biopharma, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >

These stocks that are showing activity before the opening bell on Tuesday. ↗

January 13, 2026

Via Chartmill

Millrose Properties Stock Has Surged 48% Since February Debut — So Why Did One Investor Sell a $23 Million Stake? ↗

December 07, 2025

A newly public real-estate platform is putting up numbers that look far more seasoned than its age.

Via The Motley Fool

Topics Regulatory Compliance

Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock ↗

December 07, 2025

One fund just made a bold bet on a telecom stock undergoing a big transformation

Via The Motley Fool

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Unveiling 4 Analyst Insights On Theravance Biopharma ↗

September 16, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma ↗

August 06, 2024

Via Benzinga

Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge ↗

December 07, 2025

This fund just doubled down on a stock that’s suddenly delivering the earnings momentum it’s promised for years.

Via The Motley Fool

Topics Regulatory Compliance

Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs ↗

December 07, 2025

A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors.

Via The Motley Fool

Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗

November 11, 2025

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Recap: Theravance Biopharma Q4 Earnings ↗

February 26, 2024

Via Benzinga

Here's Why Shares in Theravance Biopharma Exploded Today ↗

November 11, 2025

The company is making excellent progress on all its strategic goals.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 11, 2025

Via Benzinga

Theravance Biopharma Inc (NASDAQ:TBPH) Reports Q3 2025 Earnings Beat Amid Muted Market Reaction ↗

November 10, 2025

Theravance Biopharma (TBPH) reported Q3 2025 results, beating EPS estimates with a profit of $0.04. Revenue was slightly below forecasts. Lead drug YUPELRI achieved record sales.

Via Chartmill

Topics Earnings

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 21, 2025

Via Benzinga

Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

October 21, 2025

Via Benzinga

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

October 16, 2025

From Theravance Biopharma

Via Business Wire

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

September 12, 2025

Via Benzinga

Theravance Sales Jump 83 Percent ↗

August 12, 2025

Via The Motley Fool

Theravance Biopharma Inc (NASDAQ:TBPH) Misses Q2 2025 Revenue and EPS Estimates Amid Mixed Market Reaction ↗

August 12, 2025

Theravance Biopharma (TBPH) Q2 2025 earnings missed revenue and EPS estimates, but stock rose 3.1% after-hours. Focus remains on YUPELRI and Ampreloxetine pipeline.

Via Chartmill

Topics Earnings

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

June 17, 2025

Via Benzinga

TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024 ↗

August 05, 2024

TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 12, 2024

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Sidoti Events, LLC's Virtual June Small-Cap Conference

June 11, 2024

Via ACCESSWIRE

TBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024 ↗

May 13, 2024

TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

BTIG Research Predicts Over 118% Rally for These 3 Stocks ↗

April 15, 2024

Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.

Via InvestorPlace

Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics ↗

March 12, 2024

Although the bears see cynical opportunities, you can make give them a taste of their own medicine with these short-squeeze stocks.

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.